Table 3

Demographic and clinical characteristics of resected patients with pancreatic cancer in population-based registries*

ParameterUSAThe NetherlandsBelgiumNorwayDenmarkSloveniaEstonia
n15 628294526301005690602183
Sex, female7738 (49.5)1387 (47.1)1217 (46.3)471 (46.9)358 (51.9)293 (48.7)87 (47.5)
Age (year)66±1165±1066±1066±1167±965±1066±10
Age group
 <60 years4290 (27.5)773 (26.3)691 (26.3)253 (25.2)129 (18.7)175 (29.1)37 (20.2)
 60–69 years4982 (31.9)1086 (36.9)848 (32.2)367 (36.5)259 (37.5)201 (33.4)69 (37.7)
 70–79 years4708 (30.1)969 (32.9)915 (34.8)323 (32.1)252 (36.5)197 (32.7)68 (37.2)
 ≥80 years1648 (10.5)117 (4.0)176 (6.7)62 (6.2)50 (7.3)29 (4.8)9 (4.9)
Tumour location†
 Pancreas head10 730 (78.7)2375 (87.7)1374 (79.6)729 (83.3)521 (85.3)435 (85.8)128 (79.5)
 Pancreas body1065 (7.8)106 (3.9)127 (7.3)65 (7.4)19 (3.1)38 (7.5)17 (10.6)
 Pancreas tail1845 (13.5)228 (8.4)226 (13.1)81 (9.3)71 (11.6)34 (6.7)16 (9.9)
 Other1988 (12.7)236 (8.0)903 (34.3)130 (12.9)79 (11.5)95 (15.8)22 (12.0)
TNM stage‡
 I–II13 303 (86.9)2675 (91.9)2155 (87.9)526 (83.0)635 (92.4)406 (75.1)159 (89.8)
 III767 (5.0)148 (5.1)146 (6.0)30 (4.7)37 (5.4)46 (8.5)11 (6.2)
 IV1231 (8.1)89 (3.1)152 (6.2)78 (12.3)15 (2.2)89 (16.5)7 (4.0)
Neoadjuvant chemotherapyNA65 (2.2)82 (3.1)NA29 (4.2)2 (0.3)NA
Neoadjuvant radiotherapy677 (4.3)39 (1.3)32 (1.2)NA6 (0.9)1 (0.2)NA
Resection type
 Pancreatoduodenectomy10 759 (68.8)2472 (83.9)NANA473 (68.6)NANA
 Distal pancreatectomy2208 (14.1)298 (10.1)NANA90 (13.0)NANA
 Total pancreatectomy1855 (11.9)48 (1.6)NANA127 (18.4)NANA
 Other§806 (5.2)127 (4.3)NANA0 (0.0)NANA
Adjuvant chemotherapyNA1167 (39.6)1446 (55.0)193 (19.2)384 (55.7)172 (28.6)22 (12.0)
Adjuvant radiotherapy4610 (29.5)40 (1.4)234 (8.9)33 (3.3)1 (0.1)14 (2.3)12 (6.6)
  • *Enumeration data are shown as count (percentage (%)) and measurement data as mean±SD. Records are complete otherwise specified below.

  • †The percentages of pancreas head, body and tail are the proportions compared with the total tumour cases of pancreas head, body and tail; other: pancreas duct, overlapping lesion, NOS and other specified parts.

  • ‡Unknown TNM stage: USA, 327 (2.1%); the Netherlands, 33 (1.1%); Belgium, 177 (6.7%); Norway, 371 (36.9%); Denmark, 3 (0.4%); Slovenia, 61 (10.1%) and Estonia, 6 (3.3%).

  • §Pancreatectomy (NOS) and local resection.

  • NA, not available; NOS, not otherwise specified; TNM, tumour, node, metastasis.